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Introduction
Transforming growth factor (TGF)-β1 is a cytokine that is
involved in immune suppression, angiogenesis, apoptosis,
cell growth, and epithelial to mesenchymal transitions
(EMTs) during carcinogenesis [1–7]. TGF-β1 signals
through the TGF-β type I (TβRI) and TGF-β type II (TβRII)
transmembrane serine/threonine protein kinase receptors.
When TGF-β1 binds TβRII, TβRI is recruited to TβRII, and
TβRII phosphorylates and activates the kinase activity of
TβRI. Activated TβRI interacts with and phosphorylates a
number of proteins, thereby activating many downstream
signaling pathways, including the Smad (Sma/Mothers
Against Decapentaplegic) pathway. The Smad signaling
cascade is initiated by the phosphorylation of Smad2 or
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Abstract
Introduction: Transforming growth factor (TGF)-β1 is
proposed to inhibit the growth of epithelial cells in early
tumorigenesis, and to promote tumor cell motility and invasion
in the later stages of carcinogenesis through the induction of
an epithelial to mesenchymal transition (EMT). EMT is a
multistep process that is characterized by changes in cell
morphology and dissociation of cell–cell contacts. Although
there is growing interest in TGF-β1-mediated EMT, the
phenotype is limited to only a few murine cell lines and mouse
models.
Methods: To identify alternative cell systems in which to study
TGF-β1-induced EMT, 18 human and mouse established cell
lines and cultures of two human primary epithelial cell types
were screened for TGF-β1-induced EMT by analysis of cell
morphology, and localization of zonula occludens-1, E-cadherin,
and F-actin. Sensitivity to TGF-β1 was also determined by
[3H]thymidine incorporation, flow cytometry, phosphorylation of
Smad2, and total levels of Smad2 and Smad3 in these cell
lines and in six additional cancer cell lines.
Results: TGF-β1 inhibited the growth of most nontransformed
cells screened, but many of the cancer cell lines were
insensitive to the growth inhibitory effects of TGF-β1. In
contrast, TGF-β1 induced Smad2 phosphorylation in the
majority of cell lines, including cell lines resistant to TGF-β1-
mediated cell cycle arrest. Of the cell lines screened only two
underwent TGF-β1-induced EMT.
Conclusion: The results presented herein show that, although
many cancer cell lines have lost sensitivity to the growth
inhibitory effect of TGF-β1, most show evidence of TGF-β1
signal transduction, but only a few cell lines undergo TGF-β1-
mediated EMT.
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Smad3 by TβRI. Phosphorylated Smad2 and Smad3
associate with Smad4 and are translocated to the
nucleus, where they modulate transcription of many genes
[8–13].
In early tumorigenesis TGF-β1 inhibits the growth of
epithelial cells, and insensitivity to this growth inhibitory
effect is associated with tumor progression [5,6].
Transgenic mice expressing a dominant negative TβRII in
the epidermis and mammary glands exhibit accelerated
tumor formation and malignant conversion [14,15].
Resistance to the antiproliferative effects of TGF-β1 is
observed in head and neck squamous cell carcinomas
[16–18], lung cancer [19], gastric cancer [20–22], colon
cancer [22–25], pancreatic cancer [26], ovarian cancer
[27,28], and in some recurrent breast cancers [29,30].
This loss of sensitivity to TGF-β1 is due to mutations in or
transcriptional repression of the genes that encode TβRI
and/or TβRII. Mutations in the genes encoding Smad2
(MADH2) and Smad4 (MADH4) also contribute to the
insensitivity to TGF-β1 in many lung [31], pancreatic [32],
and colorectal [33,34] carcinomas.
In contrast to the growth inhibitory effects of TGF-β1 in
the early stages of carcinogenesis, TGF-β1 can also act
as a promoter of tumor cell invasion and metastasis in the
later stages of tumorigenesis [5,6]. Increased production
of TGF-β1 is observed in epidermal [35], gastric [36],
renal [37], breast [38–41], and prostate carcinomas [42]
when compared with normal tissues. In mice with
polyomavirus middle T antigen expression targeted to the
mammary gland, blockade of TGF-β1 by administration of
Fc:TβRII results in increased apoptosis in primary tumors
and reduced tumor cell motility, intravasation, and
metastasis [43]. Chronic exposure of mouse epidermal
cells to TGF-β1 results in loss of TGF-β1-mediated growth
inhibition and marked changes in cell morphology,
downregulation of E-cadherin and cytokeratins,
upregulation of vimentin, and formation of spindle cell
carcinomas in mice [44,45]. Further studies show that
carcinomas with excess TGF-β1 production are more
motile and invasive, and exhibit increased tumor cell
metastasis in athymic mice [36,40,45–51].
One mechanism by which TGF-β1 can promote tumor cell
motility and invasion is through the induction of EMT [52].
EMT is a complex process that involves changes in cell
morphology and dissociation of cell–cell contacts [53,54].
Cells undergoing EMT change from a cobblestone-like
appearance to an elongated, mesenchymal phenotype.
Accompanying this morphologic change is the delocaliza-
tion of adherens and tight junctional proteins from the
cell–cell junctions, and remodeling of the actin cyto-
skeleton [53,54]. Characteristics associated with EMT,
such as the dissociation of cell–cell and cell–extracellular
matrix contacts, acquisition of an elongated cell morpho-
logy, and rearrangement of the cytoskeleton, can facilitate
cell migration and invasion [55–57].
Although TGF-β1 is thought to play a key role in EMT in
vivo, the frequency of TGF-β1-induced EMT in vitro is not
known. To identify alternative cell systems in which to
study TGF-β1-mediated EMT, we screened primary
cultures of two human epithelial cell types and 18
established mouse and human cell lines for TGF-β1
responsiveness. We also included six additional cancer
cell lines as a comparison for TGF-β1 responsiveness. We
found that many of the cell strains displayed morpho-
logical changes and exhibited actin stress fiber responses
to TGF-β1. However, only in the NMuMG and MCT cells
were those changes accompanied by a loss of E-cadherin
and zonula occludens (ZO)-1 at cell–cell junctions after
48 hours of TGF-β1 treatment. Whereas all of the
nontransformed cells were growth inhibited by TGF-β1,
many of the cancer cell lines were insensitive to the
growth inhibitory effects of TGF-β1. The TGF-β1-mediated
growth inhibition was accompanied by an increase in
phosphorylated Smad2 protein levels, but this was not
unique to growth inhibited cells because changes in
Smad2 phosphorylation occurred in a majority of cells
after TGF-β1 treatment. In addition, prolonged TGF-β1
treatment induced a decrease in total Smad2 and/or total
Smad3 in some cell lines. Our findings show that,
although many cancer cells lost sensitivity to the growth
inhibitory effect of TGF-β1, only two murine cell lines
underwent TGF-β1-mediated EMT and these cells retain
growth inhibitory response to TGF-β1.
Methods
Cell lines and culture conditions
A549, BT549, DU145, H1299, HBL100, MCF10A,
MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435S,
MDA-MB-436, MDA-MB-468, NMuMG, and 4T1 cells
were purchased from American Type Culture Collection
(Rockville, MD, USA). Primary human epidermal keratino-
cytes (HEKs) from human infant foreskin were obtained
from the Vanderbilt University Skin Disease Research
Center. Primary human mammary epithelial cells (HMECs)
from two females (#1012 and #1016) were isolated and
provided by S Eltom (Meharry Medical College). Mouse
keratinocyte (MK) cells were provided by B Weissman
(University of North Carolina, Chapel Hill, NC, USA).
EpH4 cells were provided by C Arteaga (Vanderbilt
University). KC (mouse keratinocytes transformed with
K-ras) cells were derived from BALB/MK cells by Kirsten
murine sarcoma virus transformation, as described
previously [58]. HaCaT cells were provided by P Boukamp
(Deutsches Krebsforschungszentrum, Heidelberg, Germany).
MCT cells were provided by E Neilson (Vanderbilt
University). Panc-1 tumor cells were provided by L Matrisian
(Vanderbilt University). Colo357 tumor cells were provided
by M Korc (University of California, Irvine, CA, USA).R217
SCC012 and SCC028 cells were provided by D Sidransky
(Johns Hopkins University, Baltimore, MD, USA). Finally,
UNC10 cells were provided by W Yarbrough (Vanderbilt
University).
A549, Colo357, DU145, EpH4, H1299, HaCaT, HBL100,
MCT, Panc-1, and 4T1 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM)/high-glucose medium
(HyClone, Logan, UT, USA) supplemented with 10% fetal
bovine serum (FBS). BT549 cells were maintained in
RPMI-1640 medium (HyClone) supplemented with 10%
FBS and 10 µg/ml insulin. NMuMG cells were maintained
in DMEM/high-glucose medium supplemented with 10%
FBS and 10 µg/ml insulin. HMEC-1016 and HMEC-1012
were grown in DMEM:F12 medium (1:1) (GibCoBRL,
Grand Island, NY, USA) supplemented with 1% FBS,
10 µg/ml ascorbic acid, 2 nmol/l β-estradiol, 35 µg/ml
bovine pituitary extract, 1 ng/ml cholera toxin, 12.5 ng/ml
epidermal growth factor (EGF), 0.1 mmol/l ethanolamine,
0.1 mmol/l phospho-ethanolamine, 1 µg/ml hydrocortisone,
1 µg/ml insulin, 0.2 mmol/l L-glutamine, 10 nmol/l T3,
10 µg/ml transferrin, and 15 nmol/l sodium selenite.
HEKs were maintained in EpiLife medium supplemented
with human keratinocyte growth supplement (S-001-5)
and 0.06 mol/l CaCl2 (Cascade Biologics, Portland, OR,
USA). MCF-7 cells were maintained in minimal essential
medium (MEM; GibCoBRL) supplemented with 10% FBS,
10 µg/ml insulin, 1% nonessential amino acids, and
22 µg/ml sodium pyruvate. MCF10A cells were cultured in
(1:1) DMEM:F12 medium (Hyclone) supplemented with
5% horse serum, 100 ng/ml cholera toxin, 20 ng/ml EGF,
500 ng/ml hydrocortisone, and 10 µg/ml insulin. MDA-
MB-231, -361, -435S, and -436 cells were maintained in
McCoy’s 5A medium (HyClone) supplemented with 10%
FBS. MDA-MB-468 cells were grown in DMEM/high-
glucose:McCoy’s 5A medium (1:1) supplemented with
10% FBS. MK and KC cells were maintained in
DMEM/high-glucose medium supplemented with 8%
dialyzed FBS, 5 µg/ml calcium, and 4 ng/ml EGF. SCC012
and SCC028 cells were maintained in RPMI-1640
medium supplemented with 10% FBS, 1% insulin–
transferrin–selenium A, 1% L-glutamine, and 1% non-
essential amino acids. UNC10 cells were grown in DMEM/
high-glucose medium supplemented with 10% FBS, 1%
insulin–transferrin–selenium A, 1% L-glutamine, and 1%
nonessential amino acids.
All cell lines were maintained at 37°C in 5% CO2, except
for the NMuMG, MK, and KC cells, which were grown in
7% CO2.
Antibodies and other reagents
TGF-β1 was from R&D Systems (Minneapolis, MN, USA).
Antibodies to Smad2/3 (mouse) and E-cadherin (mouse)
were from BD Transduction Laboratories (San Diego, CA,
USA); antibodies to phosphorylated (Ser 465/467)
Smad2 (rabbit lot #21034 and #24432) were from
Upstate Biotechnology (Lake Placid, NY, USA); and
antibodies to ZO-1 (rat) were from Chemicon International
(Temecula, CA, USA). Smad3 (rabbit) and ZO-1 (rabbit
ZR-1) antibodies were obtained from Zymed Laboratories
Inc. (San Francisco, CA, USA). Anti-actin (rabbit) antibodies
and streptavidin–Cy3 conjugate were obtained from Sigma
(St. Louis, MO, USA). Rabbit anti-goat, goat anti-mouse,
and goat anti-rat biotinylated antibodies were obtained
from Vector Laboratories Inc. (Burlingame, CA, USA).
[3H]Thymidine incorporation assays
Subconfluent cells were treated with TGF-β1 (5 ng/ml) for
46 hours in 12-well plates and pulsed for 2 hours with
4 µCi/well [3H]thymidine (Perkin Elmer Life Sciences,
Boston, MA, USA). Cells were fixed with 1 ml 10%
trichloroacetic acid for 30 min at 25°C, followed by two
washes with 10% trichloroacetic acid. DNA was
solubilized by incubation in 600 µl 0.2 N NaOH for 30 min,
and radioactivity was counted using 200 µl solubilized
DNA in 4 ml scintillation fluid.
Flow cytometry analyses
Subconfluent cells were treated with TGF-β1 (5 ng/ml) for
48 hours and approximately 106 cells were incubated in
propidium iodide solution (50 µg/ml propidium iodide
(Sigma), 5 µg/ml RNase A, 0.1% Triton X-100, and
1 µg/ml sodium citrate) for 5–10 min. Stained cells were
analyzed using a FACS Caliber (Becton-Dickinson, San
Jose, CA, USA) and the data stored as listmode files. DNA
cell cycle histograms were analyzed and modeled using
ModFit and WinList software (Verity Software House,
Topsham, ME, USA). Fifteen thousand events were
analyzed for each sample.
Cell lysis and immunoblot analyses
After 2 hours or 48 hours of treatment with TGF-β1
(5 ng/ml), cells were lysed in protein lysis buffer
(50 mmol/l Tris pH 7.5, 100 mmol/l NaCl, 0.5% NP-40,
50 µg/ml PMSF, 4 mmol/l NaF, 0.1 mmol/l Na3VO4)
supplemented with protease inhibitors, and protein
concentrations in cell lysates were determined using the
Bradford method. Protein extracts (100 µg/lane) were
separated by 12% SDS-PAGE and transferred to
polyvinylidene fluoride membranes (Immobilon-P; Millipore,
Bedford, MA, USA). Membranes were blocked in 5%
nonfat dry milk in Tris buffered saline with Tween-20
(TTBS; 150 mmol/l NaCl, 100 mmol/l Tris, pH 7.5, 0.1%
Tween-20) for 2 hours at 25°C. Membranes to be
incubated in phosphorylated Smad2 antibodies lot
#24432 were not blocked in milk. Membranes were
incubated with primary antibodies diluted in TTBS buffer
plus 1% milk (rabbit Smad2 1:1000, phosphorylated
Smad2 1:1000 lot #21034 or 1:200 lot #24432, rabbit
Smad3 1:300, actin 1:500) for 1 hour or overnight at 4°C
Available online http://breast-cancer-research.com/content/6/3/R215for phosphorylated Smad2 lot #24432, washed for
20 min in TTBS buffer, and incubated in secondary
antibodies diluted in TTBS buffer plus 1% milk (1:10000)
for 1 hour at 25°C. Membranes were washed two times in
TTBS buffer (45 min/wash) and immunoreactive bands
were visualized by enhanced chemiluminescence.
Immunofluorescence microscopy
Subconfluent cells, grown on 22 mm2 glass cover slips
(VWR Scientific, Atlanta, GA, USA), were treated for
48 hours or 6 days with 5 ng/ml TGF-β1. After treatment,
cells were washed once with phosphate buffered saline
(PBS) and fixed with 100% cold methanol (for rat ZO-1
and E-cadherin antibody use), 4% paraformaldehyde/PBS
(for F-actin staining), or 1% paraformaldehyde/PBS (for
rabbit ZO-1 antibody use) for 20 min at 25°C. Cells were
washed four times with PBS, permeabilized by incubation
with 0.2% Triton X-100 (in PBS) for 10 min at 25°C, and
then washed two more times with PBS. For ZO-1 and
E-cadherin staining, nonspecific binding sites were
blocked by cellular incubation for 2 hours with 5% serum
(goat serum for rabbit ZO-1 and E-cadherin antibody use
and rabbit serum for rat ZO-1 antibody use) in PBS,
incubated in primary antibodies diluted in 5% serum/PBS
(rat ZO-1 1:1000, rabbit ZO-1 1:100, and E-cadherin
1:2500) for 1 hour at 25°C, followed by four washes with
PBS. Cells were incubated in appropriate biotinylated
secondary antibodies diluted in 5% serum/PBS (1:250)
for 1 hour at 25°C, washed four times with PBS, and
incubated in streptavidin-conjugated Cy3 diluted in 5%
serum/PBS (1:1000) for 1 hour at 25°C. Cells were
washed four times with PBS and nuclei were counter-
stained by incubation with 0.1 µg/ml Hoechst (33258) for
15 min at 25°C. For F-actin staining, cells were incubated
in Texas Red-X phalloidin (Molecular Probes Inc., Eugene,
OR, USA) diluted in PBS (1:200) for 30 min, washed with
PBS three times, and were counterstained with Hoechst
as described above.
After Hoechst staining, cells were washed three times
with PBS and cover slips were mounted onto 25 × 75 mm
microslides (Fisher Scientific, Pittsburgh, PA, USA) using
AquaPolyMount (Polysciences, Warrington, PA, USA).
Phase contrast images were captured using the Zeiss
Epifluorescence inverted microscope and Zeiss AxioCam
digital camera (Carl Zeiss, Jena, Germany). Fluorescent
images were captured using the Zeiss Axiophot upright
microscope (Carl Zeiss) and the Princeton Instruments
cooled CCD digital camera (Princeton Scientific
Instruments, Inc., Monmouth Junction, NJ, USA).
Results
Transforming growth factor-β β1 induced epithelial to
mesenchymal transition in NMuMG and MCT cells
To determine the frequency of TGF-β1-mediated EMT in
vitro, we performed a screen of 18 established cell lines
from human and mouse epidermis, mammary gland, lung,
pancreas, kidney, and prostate (Table 1). In addition to the
established cell lines, primary cultures of human epidermal
keratinocytes (HEKs) and human mammary gland
epithelial cells (HMEC-1012 and HMEC-1016) were also
screened (Table 1). In the present study, EMT was defined
as acquisition of a spindle-shaped morphology, loss of
ZO-1 and E-cadherin from cell–cell junctions, and
formation of actin stress fibers after TGF-β1 treatment.
Using phase contrast and immunofluorescence
microscopy, we determined that only two cell lines
underwent EMT. After 48 hours of TGF-β1 treatment, the
NMuMG and MCT cells became elongated (Fig. 1a,e,i,m),
lost E-cadherin (Fig. 1b,f,j,n) and ZO-1 (Fig. 1c,g,k,o) staining
at cell–cell junctions, and developed actin stress fibers
(Fig. 1d,h,l,p).
The primary cultures of breast epithelial cells (HMEC-1012
and HMEC-1016) acquired a spindle-shaped morphology,
whereas the primary cultures of HEKs did not change cell
morphology after 48 hours of TGF-β1 treatment
(Fig. 2a,e,i,m; and data not shown). In addition, the
HMECs and HEKs developed actin stress fibers after
treatment (Fig. 2d,h,l,p; and data not shown). However,
the HMECs and HEKs did not lose junctional E-cadherin
staining (Fig. 2b,f,j,n; and data not shown) after TGF-β1
treatment for 48 hours. These cells also had little or no
ZO-1 localized to their cell–cell junctions (Fig. 2c,g,k,o;
and data not shown).
The human breast epithelial cell line MCF10A did not
become elongated (Fig. 3a,e) or lose junctional E-cadherin
or ZO-1 staining (Fig. 3b,f,c,g) in response to 48 hours of
TGF-β1 treatment. After treatment, these cells exhibited
some actin stress fiber formation (Fig. 3d,h). However, the
MCF10A cells acquired a spindle-shaped morphology
(Fig. 3i,m) and actin stress fibers (Fig. 3l,p), and lost much
of the junctional E-cadherin and ZO-1 (Fig. 3j,n,k,o) after
TGF-β1 treatment for 6 days. The HaCaT, UNC10, A549,
Colo357, DU145, MK, KC, and 4T1 cells also exhibited
an actin stress fiber response to TGF-β1, without delocali-
zation of E-cadherin or ZO-1 from the cell–cell junctions,
similar to the MCF10A cells after 48 hours of TGF-β1
treatment (Fig. 4b,f,r,v,c,g,s,w,d,h,t,x; and data not shown).
Other cell lines screened did not exhibit any changes in
cell morphology or relocalization of E-cadherin, ZO-1, or
actin after treatment with TGF-β1. These cell lines included
SCC012, SCC028, HBL100, BT549, MCF7, MDA-MB-
231, MDA-MB-361, MDA-MB-435S, MDA-MB-436, MDA-
MB-468, H1299, Panc-1, and EpH4 cells (Fig. 4i–p; and
data not shown). A summary of the TGF-β1-induced
cellular response of the cell strains that exhibited
acquisition of a spindle-shaped morphology, loss of
junctional E-cadherin or ZO-1, or formation of actin stress
fibers is presented in Table 2.
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R218Transforming growth factor-β β1-induced inhibition of
S-phase
Previous studies analyzing TGF-β1 induction of EMT have
emphasized the stages in which TGF-β1 acts as a
promoter of carcinogenesis. It is proposed that cells first
lose sensitivity to the growth inhibitory effects of TGF-β1,
before TGF-β1 can promote EMT and cancer progression
[59]. Therefore, we examined whether there was a
correlation between TGF-β1-mediated EMT and loss of
sensitivity to the growth inhibitory effects of TGF-β1 by
examining [3H]thymidine incorporation and flow cytometry.
In [3H]thymidine incorporation experiments, it was observed
that 41% of the cell strains screened had a 0–25%
reduction in [3H]thymidine incorporation (or 75% of the
control) after 48 hours of TGF-β1 treatment. These cells
included SCC028, UNC10, HBL100, MDA-MB-361,
MDA-MB-435S, MDA-MB-436, MDA-MB-468, H1299,
Colo357, Panc-1, and 4T1 (Fig. 5 and Table 3). Similarly,
37% of the cell strains screened had a 25–75% reduction
in [3H]thymidine incorporation (or 75–25% of the control)
after 48 hours of TGF-β1 treatment. These cells included
HaCaT, SCC012, HMEC (1016), MCF10A, BT549, MCF7,
Available online http://breast-cancer-research.com/content/6/3/R215
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Table 1
Tissue origin, description, and morphology of cell strains used
Tissue origin Cell strain Description Cell morphology
Human
Epidermoid HEK Primary epidermal keratinocyte Epithelial
HaCaT Keratinocyte (abdominal skin) Epithelial
SCC012 Head and neck squamous cell carcinoma Epithelial
SCC028 Head and neck squamous cell carcinoma Spindle
UNC10 Head and neck squamous cell carcinoma Spindle
Breast HMECa Primary breast epithelium Epithelial
HBL100 Breast epithelium Epithelial
MCF10A Breast epithelium Epithelial
BT549 Breast ductal carcinoma Spindle
MCF7 Pleural metastasis of breast adenocarcinoma Epithelial
MDA-MB-231 Pleural metastasis of breast adenocarcinoma Spindle
MDA-MB-361 Brain metastasis of breast adenocarcinoma Epithelial
MDA-MB-435S Pleural metastasis of breast adenocarcinoma Spindle
MDA-MB-436 Pleural metastasis of breast adenocarcinoma Spindle
MDA-MB-468 Pleural metastasis of breast adenocarcinoma Epithelial
Lung A549 Non-small-cell lung carcinoma Epithelial
H1299 Lymph node metastasis of non-small-cell lung carcinoma Epithelial
Pancreas Colo357 Pancreatic carcinoma Epithelial
Panc-1 Pancreatic ductal carcinoma Epithelial
Prostate DU145 Brain metastasis of prostate adenocarcinoma Epithelial
Mouse
Epidermoid MK Epidermal keratinocytes Epithelial
KC K-Ras transformed epidermal keratinocytes  Epithelial
Mammary gland NMuMG Mammary gland epithelium Epithelial
EpH4 Mammary gland epithelium Epithelial
4T1 Mammary tumor Epithelial
Kidney MCT Proximal tubular epithelial Epithelial
aHuman mammary epithelial cells (HMECs) from patients #1012 and #1016. HEK, primary human epidermal keratinocytes; MK, mouse
keratinocytes.Breast Cancer Research    Vol 6 No 3 Brown et al.
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Figure  1
NMuMG and MCT cells underwent transforming growth factor (TGF)-
β1-mediated epithelial to mesenchymal transition. Phase contrast
images of (a,e) NMuMG and (i,m) MCT cells with (TGF-β1) and
without (control) TGF-β1 treatment (5 ng/ml) for 48 hours.
Immunofluorescence detection of (b,f,j,n) E-cadherin, (c,g,k,o) zonula
occludens (ZO)-1, and (d,h,l,p) F-actin in NMuMG and MCT cells
treated with 5 ng/ml TGF-β1 (TGF-β1) or without TGF-β1 (control) for
48 hours. TGF-β1 induced cell elongation, loss of cortical actin and
junctional E-cadherin and ZO-1 staining, and formation of actin stress
fibers in NMuMG and MCT cells. Micrographs are representative of at
least three independent experiments.
Figure 2
Transforming growth factor (TGF)-β1 induced spindle-shaped
morphology in nontransformed human mammary epithelial cells
(HMECs) and human epidermal keratinocytes (HEKs). Phase contrast
images of (a,e) HEK and (i,m) HMEC cells with (TGF-β1) and without
(control) TGF-β1 treatment (5 ng/ml) for 48 hours. Immuno-
fluorescence detection of (b,f,j,n) E-cadherin, (c,g,k,o) zonula
occludens (ZO)-1, and (d,h,l,p) F-actin in HEK and HMEC cells
treated with 5 ng/ml TGF-β1 (TGF-β1) or without TGF-β1 (control) for
48 hours. TGF-β1 induced cell elongation and formation of actin stress
fibers in the HEK and HMEC cells. However, junctional E-cadherin
staining remained intact after TGF-β1 treatment. ZO-1 was not
detected in the HEK cells and little was observed in the HMEC cells
with or without TGF-β1 treatment. Micrographs are representative of at
least three independent experiments.
Table 2
Summary of transforming growth factor-β β1-induced cellular responses in vitro
TGF-β1-induced responsea
Acquisition of  Loss of junctional  Actin stress fiber 
Cell strain spindle shapeb E-cadherinc Loss of junctional ZO-1c formationc
HEK ± – N/Ad ±
HMECe ± – N/Ad +
HaCaT – – – ±
Colo357 – – – ±
Panc-1 – – – –
NMuMG + + + +
MCT + + + +
aTreatment with 5 ng/ml transforming growth factor (TGF)-β1 for 48 hours. bDetermined by phase contrast microscopy. cDetermined by E-cadherin,
zonula occludens (ZO)-1, or F-actin immunofluorescence. dHuman epidermal keratinocytes (HEKs) and human mammary epithelial cells (HMECs)
exhibited little to no junctional ZO-1 staining in the absence of TGF-β1 treatment. eHMECs from patients #1012 and #1016. Cellular responses to
TGF-β1 designated by + (strong), ± (weak), or – (negative).MDA-MB-231, A549, DU145, and EpH4 (Fig. 5 and Table3).
Only 22% of the cell strains screened showed greater
than a 75% reduction in [3H]thymidine incorporation (or
25% of the control) after 48 hours of TGF-β1 treatment
(Fig. 5 and Table 3). These cells included HEK, HMEC
(1012), MK, KC, NMuMG, and MCT (Fig. 5 and Table 3).
Of note, established cell lines constituted 95% of the cells
that did not have greater than 75% reduction in
[3H]thymidine after TGF-β1 treatment (Fig. 5 and Table 3).
Most of the cell lines that did not have a greater than 75%
reduction in [3H]thymidine incorporation after TGF-β1
treatment, did not exhibit changes in morphology or changes
in actin, E-cadherin, or ZO-1 localization in this screen
(Figs 1–5; and data not shown). Only the UNC10, A549,
and DU145 cell lines did not have reduced [3H]thymidine
incorporation of greater than 75% and had increased actin
stress fiber formation after TGF-β1 treatment (Figs 4 and 5;
and data not shown). However, there was no change in
ZO-1 localization in these cells (data not shown). In
comparison, all of the cell lines that had decreased
[3H]thymidine incorporation had increased actin stress
fiber formation after TGF-β1 treatment (Fig. 1d,h,l,p;
Fig. 2d,h,l,p; Fig. 3d,h,I,p; Fig. 4d,h,t,x; Fig. 5; and data not
shown). These cells included the HaCaT, MCF10A,
Colo357, MK, KC, NMuMG, 4T1, and MCT cells, and the
primary cultures of HMEC-1012 and HEK cells.
Flow cytometry was also performed on cells treated with
TGF-β1 for 48 hours to confirm the data generated by
[3H]thymidine incorporation. The data generated by flow
cytometry experiments were consistent with those of [3H]
thymidine incorporation (Figs 5 and 6, and Table 3). Fig. 6
includes histograms that were representative of cell
strains with 0–25% (MDA-MB-436), 25–75% (EpH4), and
75–100% (NMuMG) reduction in S-phase after 48 hours
of TGF-β1 treatment, when compared with the control cells.
Transforming growth factor-β β1-mediated Smad2
phosphorylation did not correlate with S-phase reduction
To determine the relationship of Smad2 phosphorylation
with reduction in S-phase and EMT, after TGF-β1 treatment,
we analyzed phosphorylated Smad2 protein levels.
Western analyses of protein extracts showed that, after
2 hours of treatment with TGF-β1, phosphorylated Smad2
protein levels increased in all of the cell strains screened
except for the MCF7, MDA-MB-361, and MDA-MB-435S
cells when normalized to actin (Fig. 7 and Table 3). After
treatment with TGF-β1 for 48 hours, levels of phosphory-
lated Smad2 remained elevated in the cells with increased
levels of phosphorylated Smad2 after 2 hours of treatment,
except HMEC (1016), HBL100, MCF10A, MDA-MB-436,
H1299, MK, and MCT when normalized to actin (Figs 7
and 8, and Table 3). Immunoblot analysis of the MCF7,
MDA-MB-361, and MDA-MB-435S cells with the
phosphorylated Smad2 antibody (lot #21034) resulted in
a band (indicated by an asterisk) that migrated higher than
the phosphorylated Smad2 protein (Fig. 7).
Cell strains that exhibited TGF-β1-induced phosphorylation
of Smad2 did not necessarily exhibit a reduction in
[3H]thymidine uptake. These cell strains included
SCC028, MDA-MB-436, MDA-MB-468, and H1299
(Figs 5 and 7, and Table 3). Although the MCF7 cells had
[3H]thymidine uptake of 59% of the control after 48 hours
of TGF-β1 treatment, an increase in phosphorylation of
Smad2 by Western analysis was not observed at 2 hours
or at 48 hours (Figs 5, 7 and 8, and Table 3).
Prolonged transforming growth factor-β β1 treatment led
to decreased total Smad2 and Smad3 protein levels in
many cell strains
Total Smad2 and Smad3 protein levels decreased with
TGF-β1 treatment in 51% and 48% of the cell lines,
respectively (Fig. 8). Total Smad2 levels decreased in
HEK, HaCaT, SCC012, UNC10, BT549, MDA-MB-231,
MDA-MB-361, MDA-MB-435S, H1299, Colo357,
NMuMG, EpH4, 4T1, and MCT cells when normalized to
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Figure 3
Elongation and loss of junctional E-cadherin and zonula occludens
(ZO)-1 after prolonged transforming growth factor (TGF)-β1 treatment
in MCF10A cells. Phase contrast images of MCF10A cells treated with
(TGF-β1) or without (control) 5 ng/ml TGF-β1 for (a,e) 48 hours or
(i,m) 6 days. Immunofluorescence detection of (b,f,j,n) E-cadherin,
(c,g,k,o) ZO-1, and (d,h,l,p) F-actin in MCF10A cells treated with
TGF-β1) or without (control) 5 ng/ml TGF-β1 for 48 hours or 6 days.
TGF-β1 treatment induced cell elongation and formation of actin stress
fibers in the MCF10A cells after 6 days of TGF-β1 treatment but not
after 48 hours. MCF10A cells also lost some junctional E-cadherin and
ZO-1 after 6 days of treatment with TGF-β1. Micrographs are
representative of at least three independent experiments.Breast Cancer Research    Vol 6 No 3 Brown et al.
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Figure 4
Transforming growth factor (TGF)-β1 did not induce epithelial to mesenchymal transition in Colo357, Panc-1, or HaCaT Cells. Phase contrast
images of (a,e) Colo357, (i,m) Panc-1, and (q,u) HaCaT cells treated with (TGF-β1) or without (control) 5 ng/ml TGF-β1 for 48 hours.
Immunofluorescence detection of (b,f,j,n,r,v) E-cadherin, (c,g,k,o,s,w) zonula occludens (ZO)-1, and (d,h,l,p,t,x) F-actin in Colo357, Panc-1, and
HaCaT cells treated with (TGF-β1) or without (control) 5 ng/ml TGF-β1 for 48 hours. TGF-β1 treatment induced cell enlargement and formation of
actin stress fibers in the Colo357 cells. However, junctional E-cadherin and ZO-1 remained intact after TGF-β1 treatment. Changes in cell
morphology, E-cadherin, ZO-1, or actin localization were not observed in the Panc-1 and HaCaT cells. Micrographs are representative of two
experiments.
Figure 5
Many cancer cell lines were not growth inhibited by transforming growth factor (TGF)-β1. Human primary cells and human and mouse established
cell lines were treated with TGF-β1 (5 ng/ml) for 48 hours. The cells were then pulsed for 2 hours with [3H]thymidine, and incorporated radioactivity
was quantified. Results are presented as the average percentage of control (untreated cells) incorporation (± standard error) from three independent
experiments with 6–12 replicates per experiment. The average percentage of control [3H]thymidine incorporation was calculated by dividing the
average [3H]thymidine incorporation of TGF-β1-treated cells (from three independent experiments) by the average [3H]thymidine incorporation of
nontreated cells (from three independent experiments) and then multiplying by 100%. Epid, epidermoid; Kid, kidney; Panc, pancreas; Pros, prostate.actin (Fig. 8). Total Smad3 levels decreased in HEK, HMEC
(1012 and 1016), HaCaT, SCC012, SCC028, UNC10,
BT549, MDA-MB-231, MDA-MB-436, A549, EpH4, and
4T1 cells when normalized to actin (Fig. 8).
Decreased total Smad2 and total Smad3 protein levels
did not correlate with an increased reduction in S-phase
after TGF-β1 treatment for 48 hours. For instance, the
HMEC (1012), MK, and KC cells had a 87%, 81%, and
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Table 3
Summary of transforming growth factor-β β1-mediated Smad signaling and effect on S-phase in vitro
TGF-β1-mediated responsea
S-phase (% of control ± standard error)
Increase in  Decrease in total  Decrease in total 
Cell strain phosphorylated Smad2b Smad2c Smad3c [3H]Td Flowe
HEK + – – 2 ± 0.3 72 ± 9
HaCaT + + + 50 ± 4 86 ± 11
SCC012 + + + 63 ± 2 89 ± 2
SCCO28 + – + 95 ± 1 105 ± 3
UNC10 + + + 82 ± 5 96 ± 1
HMEC 1012 + – + 13 ± 6 47 ± 6
HMEC 1016 –* – + 35 ± 0.4 70 ± 2
HBL100 –* – – 87 ± 5 103 ± 3
MCF10A –* – – 46 ± 5 78 ± 8
BT549 + + + 74 ± 3 N/Ag
MCF7 – – – 59 ± 3 81 ± 4
MDA-MB-231 + + + 60 ± 1 83 ± 0.1
MDA-MB-361 – + – 95 ± 3 98 ± 2
MDA-MB-435S – + – 95 ± 4 96 ± 3
MDA-MB-436 –* – + 99 ± 1 98 ± 8
MDA-MB-468 + – – 96 ± 4 98 ± 1
A549 + – + 72 ± 4 96 ± 9
H1299 –* + – 101 ± 4 107 ± 3
Colo357 + + –f 82 ± 7 69 ± 5
Panc-1 + – – 92 ± 4 95 ± 6
DU145 + – – 68 ± 4 83 ± 8
MK –* – – 19 ± 2 38 ± 7
KC + – – 11 ± 3 27 ± 4
NMuMG + + – 8 ± 1 17 ± 1
EpH4 + + + 55 ± 0.4 84 ± 4
4T1 + + + 80 ± 6 91 ± 1
MCT –* + – 24 ± 3 87 ± 8
aTreatment with 5 ng/ml transforming growth factor (TGF)-β1 for 48 hours. bSimilar results obtained after 2 hours TGF-β1 treatment except those
designated by an asterisk (detected increased phosphorylated Smad2 after 2 hours of TGF-β1 treatment). cNo decrease in total Smad2 or total
Smad3 was detected after 2 hours of TGF-β1 treatment. d[3H]Thymidine ([3H]T) experiments performed at least three times with 6–12 replicates.
Results are presented as the average percent of control of three independent experiments. eFlow cytometry experiments performed at least three
times in triplicate. Results are presented as the average percent of control of three independent experiments. fAn increase in total Smad3 was
observed in Colo357 cells 48 hours after TGF-β1 treatment. gAccurate flow cytometry analysis could not be performed on BT549 cells because
multiple populations of cells were present in the culture. Cellular responses to TGF-β1 designated as + (positive response) or – (negative
response). HEK, human epidermal keratinocyte; HMEC, human mammary epithelial cell; KC, mouse keratinocytes transformed with K-ras; MK,
mouse keratinocyte.89% reduction in [3H]thymidine incorporation, respectively,
whereas there was no decrease in total Smad2 protein
levels after 48 hours of TGF-β1 treatment (Figs 5 and 8,
and Table 3). Similarly, the MK, KC, MCT, and NMuMG
cells had 81%, 89%, 76%, and 92% reductions in
[3H]thymidine incorporation, respectively, whereas there
was no decrease in total Smad3 protein levels after
48 hours of TGF-β1 treatment (Figs 5 and 8, and Table 3).
In contrast, the HEK cells had a 98% reduction in
[3H]thymidine incorporation and had no reduction of total
Smad2 or Smad3 after 48 hours of TGF-β1 treatment
(Figs 5 and 8, and Table 3).
Also, decreased total Smad2 and Smad3 protein levels
did not correlate with an increase in the levels of phosphory-
lated Smad2 protein after TGF-β1 treatment (Figs 7 and
8, and Table 3). An increase in phosphorylated Smad2
protein levels occurred in all cell strains screened after
2 hours of TGF-β1 treatment except for the MCF7, MDA-
MB-361, and MDA-MB-435S cells (Fig. 7), whereas only
a subset of those had decreased total Smad2 and/or
Smad3 protein levels after TGF-β1 treatment for 48 hours
(Fig. 8 and Table 3). Additionally, the MDA-MB-361 and
the MDA-MB-435S cells did not have increased
phosphorylated Smad2 levels or decreased total Smad3
Breast Cancer Research    Vol 6 No 3 Brown et al.
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Figure 6
Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains. Human primary cells and human and mouse
established cell lines were treated with (TGF-β1) or without (control) 5 ng/ml TGF-β1 for 48 hours. The cells were then harvested and incubated
with propidium iodide, and DNA content was determined using a FACS Caliber (Becton-Dickinson). Data were modeled and analyzed using
ModFit and WinList software (Verity Software House). Fifteen thousand events were analyzed for each sample. Representative histograms are
presented illustrating cells that had a robust decrease in S-phase (NMuMG), modest decrease in S-phase (EpH4), and no decrease in S-phase
(MDA-MB-436) as a result of TGF-β1 treatment. G0/G1 and G2 phases are indicated by black shading and S phase is indicated by gray shading
on the histograms. The percentage of cells in G0/G1 and in S phases of the cell cycle are indicated. Three independent experiments were
performed with three replicates per experiment.levels, but they did exhibit decreased total Smad2 levels
after 48 hours of TGF-β1 treatment (Figs 7 and 8, and
Table 3).
The decrease in total Smad2 and Smad3 protein levels,
observed after TGF-β1 treatment, did not associate with
the ability of the cell line to undergo TGF-β1-mediated
EMT. NMuMG and MCT cells underwent EMT (Fig. 1) and
they both exhibited decreased total Smad2 and no
decrease in total Smad3 protein levels after TGF-β1
treatment for 48 hours (Fig. 8). The other cell lines that
had decreased total Smad2 and no decrease in total
Smad3 levels after TGF-β1 treatment did not undergo
TGF-β1-induced EMT (Figs 2–4 and 8, and Table 3; and
data not shown).
Discussion
TGF-β1 is an inhibitor of epithelial cell growth in the early
stages of carcinogenesis. However, it also promotes
tumor cell invasion and metastasis through the induction
of EMT [52]. Many studies on the mechanism of TGF-β1-
induced EMT are limited to a few murine cell lines and
mouse models. Therefore, to identify alternative cell systems
in which to study TGF-β1-induced EMT, we performed a
TGF-β1 sensitivity screen using a panel of human primary
cells and established human and mouse cell lines.
The TGF-β1-induced morphologic changes observed in
the NMuMG, MCT, and HMEC cells 48 hours after TGF-
β1 treatment are consistent with changes seen during
EMT (Fig. 1a,e,i,m; Fig. 2i,m; and data not shown) [53,54].
Available online http://breast-cancer-research.com/content/6/3/R215
R225
Figure 7
Transforming growth factor (TGF)-β1 induced Smad2 phosphorylation in many cancer and noncancer cell strains. Twenty-four human and mouse
established cell lines and three primary human cell cultures were treated with TGF-β1 (5 ng/ml) for 2 hours. Extracts from control (–) and treated
(+) cells were prepared and subjected to immunoblot analyses using antibodies for phosphorylated Smad2 (Ser 465/467), total Smad2, total
Smad3, or actin. A signal of higher molecular weight, that is not phosphorylated Smad2, is indicated by an asterisk.Changes in cell morphology, from a cobblestone-like
appearance to more elongated shape, and actin stress
fiber formation, were observed in the NMuMG and MCT
cells, and in primary cultures of HMECs (Fig. 1a,d,e,h,i,l,m,p;
Fig. 2i,l,m,p; and data not shown). However, only the
NMuMG and MCT cells lost E-cadherin and ZO-1 staining
at the cell–cell junctions after 48 hours of TGF-β1 treat-
ment (Fig. 1b,f,j,n,c,g,k,o). E-cadherin is a protein found at
adherens junctions that allows for cell–cell adherence,
and ZO-1 is a tight junctional protein that forms a selective
barrier between cells. Loss of these proteins at cell–cell
junctions is used as a marker of EMT [54,60–63]. Cortical
actin is a measure of cell integrity and loss thereof, or
formation of actin stress fibers, is also used to define EMT
[63,64]. Therefore, we concluded that only the NMuMG
and MCT cells underwent TGF-β1-mediated EMT, after
48 hours of treatment, in this screen. Results from
previous studies also show that NMuMG and MCT cells
undergo TGF-β1-mediated EMT [60,61,63–65]. Other
studies reported that TGF-β1-mediated EMT occurs in
HaCaT, Colo357, and Panc-1 cells 48 hours after TGF-β1
treatment [66,67]; however, they did not undergo TGF-β1-
induced EMT according to the conditions used in the
present study (Fig. 4). Other cell lines screened in the
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Figure 8
Prolonged transforming growth factor (TGF)-β1 treatment induced a decrease in total Smad2 and/or Smad3 in many cell strains. Twenty-four
human and mouse established cell lines and three primary human cell cultures were treated with TGF-β1 (5 ng/ml) for 48 hours. Extracts from
control (–) and treated (+) cells were prepared and subjected to immunoblot analyses using antibodies for phosphorylated Smad2 (Ser 465/467),
total Smad2, total Smad3, or actin.study formed actin stress fibers with TGF-β1 treatment,
but they did not lose ZO-1 from cell–cell junctions
(Fig. 3c,d,g,h; and data not shown). We did not examine
E-cadherin localization in all of the cell strains because not
all of the cell strains exhibited morphologic changes, with
TGF-β1 treatment, that were indicative of EMT.
Unlike the mouse NMuMG and MCT cells, none of the 14
human cell lines with an epithelial morphology screened
underwent TGF-β1-mediated EMT within 48 hours of TGF-
β1 treatment. The MCF10A human breast epithelial cell
line took 6 days to undergo a morphologic change, lose
junctional E-cadherin and ZO-1, and form actin stress
fibers with TGF-β1 treatment (Fig. 3i–p). However, this
extended treatment with TGF-β1 to induce EMT is not
consistent with previous reports that used times up to and
including 48 hours [60,61,66,67]. It may be that the
extended treatment with TGF-β1 is necessary to activate
secondary and tertiary signaling pathways that are not
activated within 48 hours. The Panc-1, Colo357, and
HaCaT cells were treated with TGF-β1 for longer than
48 hours because they were shown to undergo TGF-β1-
induced EMT in previous reports [66,67]. However, these
cell lines did not undergo EMT when treated with TGF-β1
for 72 hours (data not shown). These data could suggest
that human cells are more resistant to TGF-β1-mediated
EMT. Alternatively, the TGF-β1 treatment times were not
long enough to induce EMT, the small sample size used
may not be representative, or the cells may not have the
genetic alterations necessary for TGF-β1 to induce EMT.
Activation of non-Smad signaling pathways is also implica-
ted in TGF-β1-mediated EMT. Many studies have shown a
requirement for activated Ras/Raf/mitogen-activited protein
kinase for TGF-β1-mediated EMT in human, rat, or mouse
epidermal, pancreas, intestine, liver, prostate, and mammary
epithelial cells [67–76]. In the mouse mammary gland
epithelial cell line EpH4, TGF-β1 induces EMT and tumor
formation in mice only when cells express oncogenic
H-Ras [73]. Furthermore, it has been shown that TGF-β1
can activate Ras, and increased H-Ras levels are required
for nuclear accumulation of Smad2 [70]. Additionally,
signaling through integrin β1 [68] and activation of EGF
receptor [62], RhoA [61], p38 mitogen-activited protein
kinase [77], and phosphatidylinositol 3-kinase [60,70,71]
pathways are involved in or required for TGF-β1-induced
EMT.
The lack of TGF-β1-mediated EMT in the human cells
does not necessarily refute a role for TGF-β1 in promoting
EMT in vivo in human tumors. Human epithelial tumors can
undergo mesenchymal conversions, providing a potential
role for EMT in human metastasis. It has been shown that
excess TGF-β1 can promote EMT in human tumors in
vivo. Increased levels of TGF-β1 are observed in many
human tumors [35–40,42,51,78–80], are often localized
to the advancing edges of primary tumors and metastases,
and are associated with poor clinical outcome [39,41].
It is somewhat unexpected that TGF-β1-induced EMT
occurred in nontransformed cell lines, such as the
NMuMG and MCT cells, because in vivo mouse studies
show that TGF-β1 promotes tumor cell invasion and
metastasis in the later stages of carcinogenesis [5,6]. In
one of these studies, targeted expression of TGF-β1 to
mouse suprabasal keratinocytes results in resistance to
the formation of benign skin tumors, after long-term chemical
carcinogenesis treatment. However, benign papillomas that
develop become malignant at an accelerated rate and
metastasis occur more rapidly than spontaneous tumors in
control mice. Additionally, there are a high incidence of
spindle cell carcinoma development in these mice,
pointing to TGF-β1-induction of EMT in vivo [38].
NMuMG and MCT cells may have the genetic alterations
that allow for TGF-β1-mediated EMT to occur.
Many studies on TGF-β1-mediated EMT have emphasized
that TGF-β1 promotes carcinogenesis in stages. It is
proposed that cells first lose sensitivity to the growth
inhibitory effects of TGF-β1, and subsequently TGF-β1
can promote tumor progression and EMT [59]. MMH-D3
murine hepatocytes and EpH4 murine mammary gland
epithelial cells undergo TGF-β1-mediated EMT only when
rendered insensitive to TGF-β1-induced cell cycle arrest
or apoptosis, by infection with active H-Ras
[59,70,73,81]. However, the present study does not
support this model because it shows that resistance to the
growth inhibitory effects of TGF-β1 is not a prerequisite
for TGF-β1-mediated EMT. The NMuMG and MCT cells
exhibited a decrease in S-phase and underwent EMT after
48 hours of TGF-β1 treatment (Figs 1, 5, and 6). Consistent
with the present study were experiments performed by
Nicolas and coworkers [72] that showed that increased
Smad3 in MDCK cells restored growth inhibitory
responses to TGF-β1 but did not revert cells from a
mesenchymal to an epithelial phenotype. Additionally,
Chang and coworkers [49] observed that increased TGF-
β1 expression in sarcoma cells increased cell tumori-
genicity while inhibiting cell proliferation.
The trends observed with the analysis of the flow
cytometry data were consistent with the [3H]thymidine
incorporation data (Figs 5 and 6 and Table 3). However,
the values for the percentage of the control cells in S-
phase were not identical between [3H]thymidine
incorporation and flow cytometry for each cell strain. This
discrepancy can be accounted for by the fact that the data
were generated using two different methodologies.
[3H]thymidine incorporation examines DNA synthesis
during the last 2 hours of the 48-hour period, whereas
flow cytometry examines DNA synthesis at the 48-hour
time-point. Although the numeric data generated from the
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experiments were not the same, the trends of TGF-β1-
induced decreases in DNA synthesis were consistent.
All but three of the cell strains screened had an increase in
phosphorylated Smad2 protein levels after 2 hours of
TGF-β1 treatment, but not all of the cell lines that had
increased phosphorylation of Smad2 had reduced
S-phase after 48 hours of TGF-β1 treatment. The
SCC028, MDA-MB-436, MDA-MB-468, and H1299 cells
had an increase in phosphorylated Smad2 levels after
2 hours of TGF-β1 treatment, but they exhibited
decreases in S-phase of only 5%, 1%, 4%, and 4%,
respectively (Figs 5–7 and Table 3). The lack of S-phase
decrease upon 48 hours of TGF-β1 treatment may point
to inactivation of or mutations in downstream proteins that
could abolish TGF-β1-mediated growth inhibition in these
cells. The MCF7 cells did not exhibit an increase in
phosphorylated Smad2 protein levels after 2 hours of
TGF-β1 treatment, but there was a 41% decrease in S-
phase on 48 hours of TGF-β1 treatment (Figs 5–7 and
Table 3). This decrease in S-phase is not as great a
decrease as was exhibited by some of the other cell
strains when treated with TGF-β1 for 48 hours. The
decrease could be explained by very low levels of
phosphorylated Smad2 increase on TGF-β1 treatment
that was not detected by immunoblot analysis.
Alternatively, it is possible that the TGF-β1 signal was
propagated by phosphorylation of Smad3.
Smad2 is not solely responsible for the propagation of TGF-
β1 signals. Similar to Smad2, on TGF-β1 binding to the
TβRII, Smad3 is phosphorylated by the TβRI, forms a
complex with Smad4, translocates to nucleus, and
regulates the activation of TGF-β1 target genes. However,
mutations or deletions in Smad3 are rare in human cancers.
Reports by Graham and coworkers [82] and Xu and
coworkers [83] suggest that loss of Smad3 may largely be
responsible for the nonresponsiveness of some cells to
TGF-β1. The proliferation, migration, and invasion of normal
extravillous trophoblast cells are under the control of TGF-
β1. However, premalignant and malignant trophoblast cells,
that have lost the Smad3 protein but retain functional
Smad2, are resistant to the antiproliferative and anti-invasive
effect of TGF-β1. It is therefore possible that the attenuation
of inhibition of S-phase or the induction of EMT by TGF-β1
in the present study may be a result of mutation or loss of
Smad3, even though the cells have increased
phosphorylation of Smad2 on TGF-β1 treatment.
Interestingly, decreased total Smad2 and Smad3 protein
levels were observed after TGF-β1 treatment regardless of
changes in the levels of phosphorylated Smad2 protein or
of whether cell proliferation was inhibited by TGF-β1
(Figs 5–8). Similar to our findings, decreased total Smad2
protein levels were reported in COS-1 monkey kidney
cells after TGF-β1 treatment [84]. In that report, the
proteasome inhibitors MG-132 or lactacystin blocked
Smad2 from TGF-β1-induced degradation. In addition,
Smad3 decreases have been reported during TGF-β1-
induced EMT in MDCK cells [72,85] and after TGF-β1
treatment of human lung epithelial cells [86]. In these
studies, MDCK cells become refractory to the growth
inhibitory effects of TGF-β1 [72,85]. TGF-β1 treatment of
primary human fibroblasts and HaCaT cells also leads to
decreased total Smad3 protein levels [87,88].
A negative feedback loop could explain the decreases in
total Smad2 and Smad3 protein levels after 48 hours of
TGF-β1 treatment. The E3 ubiquitin ligase Smurf has been
shown to interact with Smads and promote their ubiquiti-
nation [89,90]. In this model, phosphorylated, nuclear
Smad2 is ubiquitinated by Smurf2 and degraded by
proteasomes [89,90]. Smad7 also interacts with Smurf2
and induces TGF-β receptor degradation [91,92].
Phosphorylated Smad3 is also ubiquitinated by the ROC1-
SCFFbw1a E3 ligase complex, and subsequently degraded
in the proteasome [88]. In order to prevent continuous
Smad signaling in the absence of TGF-β1 stimulation,
Smad2 and Smad3 are negatively regulated by a number
of proteins. Smad6 and Smad7 inhibit Smad2 and Smad3
activation by competing with Smad2 and Smad3 for
binding to the TGF-β receptors [93]. Smad6 and Smad7
are induced by activation of TGF-β1 signaling and form a
negative feedback loop [94–96]. However, the mechanism
of decrease in total Smad2 and/or Smad3 in different cell
strains on prolonged TGF-β1 treatment remains unclear.
Conclusion
TGF-β1 induction of EMT is a rare occurrence in vitro and
is not limited to transformed cell lines. In fact, TGF-β1-
mediated EMT was only observed in nontumorigenic cells
in the present study. Furthermore, there does not appear
to be a correlation between loss of TGF-β-mediated
growth inhibition and EMT. The inability of TGF-β1 to
induce EMT was not due to a total loss of TGF-β1
signaling, as was evidenced by induction of Smad2
phosphorylation. In conclusion, our data indicate that the
in vitro models used to study TGF-β1 induction of EMT
may not be as relevant to in vivo cancer progression as
was previously assumed in the field.
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